Clinical Trial Update: Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating safety, pharmacokinetics, and the transmission-reducing activity of the monoclonal antibody TB31F in Mali.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria
• Plasmodium Falciparum Malaria

Drugs mentioned

• TB31F

Snippet

Sponsor: Radboud University Medical Center | Conditions: Malaria,Falciparum | Phase 1, Phase 2 | Status: COMPLETED